FENC
NASDAQFennec Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$10.01-0.46 (-4.44%)
2026-07-162026-10-16
News · 26 weeks700%
2026-04-192026-10-11
Mix3090d
- Insider25(83%)
- Earnings2(7%)
- SEC Filings2(7%)
- Other1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Fennec Pharmaceuticals Inc.4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Fennec Pharmaceuticals Inc.4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Fennec Pharmaceuticals Inc.4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Fennec Pharmaceuticals Inc.4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Fennec Pharmaceuticals Inc.4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Medical Officer Sayad Pierre Sargis was granted 168 shares, increasing direct ownership by 2% to 9,687 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Commercial Officer Evans Terry L was granted 168 shares, increasing direct ownership by 0.78% to 21,687 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.71% to 243,009 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 67,461 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.63% to 24,800 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~ ~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~ ~ Objective Responses Observed in 23 of 24 Evaluable Patients (95.8%); Prospective Pharmacokinetic Analyses Provide New Mechanistic Insight Supporting the Six-Hour PEDMARK® Administration Interval for Pediatric & Adolescent and Young Adult (AYA) Patients ~ ~ Building Upon the Pivotal Children’s Oncology Group (COG) Protocol ACCL0431 & SIOPEL 6 Studies, STS-J01 Represents Third Study to Dem
- INSIDERDirector Brughera Marco Maria exercised 15,545 shares at a strike of $2.11 and sold $159,958 worth of shares (15,545 units at $10.29) as part of a pre-agreed trading plan (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERFormer Director Raykov Rosty was granted 2,778 shares and sold $121,100 worth of shares (10,000 units at $12.11) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 124,411 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Medical Officer Sayad Pierre Sargis was granted 168 shares and sold $146,160 worth of shares (12,000 units at $12.18), decreasing direct ownership by 55% to 9,519 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Commercial Officer Evans Terry L was granted 168 shares, increasing direct ownership by 0.79% to 21,519 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.64% to 24,644 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 66,302 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.71% to 241,306 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Andrade Robert sold $883,500 worth of shares (75,000 units at $11.78) as part of a pre-agreed trading plan and exercised 21,928 shares at a strike of $5.10, decreasing direct ownership by 18% to 239,603 units (SEC Form 4) (tax withholding)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- SECSEC Form 10-Q filed by Fennec Pharmaceuticals Inc.10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK® Demand Carried into Third Quarter 2026 as Field Sales Expansion Efforts Continue to Validate Commercial Growth Strategy ~ ~ Real-World Evidence Presented at ASCO 2026 Reinforced that PEDMARK® Can Be Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today rep
- PRFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date: Tuesday, August 11, 2026Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/tjdvggzn Participant Link: https://register-conf.media-server.com/register/BI48fe753d5b224919a74621f21
- INSIDERFormer Director Raykov Rosty sold $95,800 worth of shares (10,000 units at $9.58) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 131,633 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Medical Officer Sayad Pierre Sargis was granted 168 shares, increasing direct ownership by 0.79% to 21,351 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
FENC FAQ
6 questionsWhat does Fennec Pharmaceuticals Inc. do?
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Where does FENC stock trade?
Fennec Pharmaceuticals Inc. (FENC) is listed on NASDAQ.What sector and industry is FENC in?
Fennec Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about FENC?
Fennec Pharmaceuticals Inc. has had 5 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $1600.00 price target on 2026-02-12. Recent price targets range from $1100.00 to $1600.00.What companies are similar to FENC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare FENC side-by-side with any of them on Quantisnow.How can I track FENC on Quantisnow?
Quantisnow aggregates Fennec Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FENC to receive live email and push alerts on every new disclosure.